Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.50 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.50 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | RGS12 | O14924 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | THPO | P40225 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4402323 | 0.90 | AKR1B1 (0.62) | AKR1B1TDP1CYP1A2CYP2C19LMNA | |
| SCHEMBL70565 | 0.87 | AKR1B1 (0.71) | AKR1B1TDP1CYP1A2CYP2C19LMNA | |
| Hydrochloric Acid SCHEMBL8922940 | 0.85 | AKR1B1 (0.68) | AKR1B1TDP1CYP1A2CYP2C19LMNA | |
| SCHEMBL30638471 | 0.84 | KEAP1 (0.63) | AKR1B1TDP1CYP1A2CYP2C19LMNA | |
| SCHEMBL4407150 | 0.84 | KEAP1 (0.63) | AKR1B1TDP1CYP1A2CYP2C19LMNA | |
| Phenylacetic Acid SCHEMBL29278083 | 0.83 | AKR1B1 (0.74) | AKR1B1TDP1CYP4F2CYP4A11LMNA | |
| SCHEMBL1401775 | 0.83 | AKR1B1 (0.60) | AKR1B1TDP1ACMSDCYP1A2CYP2C19 | |
| SCHEMBL239199 | 0.82 | TDP1 (0.65) | TDP1CYP4F2CYP4A11ACMSDLMNA | |
| SCHEMBL15042342 | 0.82 | AKR1B1 (0.54) | AKR1B1TDP1CYP1A2CYP2C19LMNA | |
| SCHEMBL27856647 | 0.82 | AKR1B1 (0.54) | AKR1B1TDP1CYP1A2CYP2C19LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11365192-B2 | Pyridine compound substituted with azole | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2021-04-29 | — | — | US | disclosed |
| EP-3666766-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | Taisho Pharmaceutical Co., Ltd. (JP) | 2020-06-17 | — | — | EP | disclosed |
| CN-110914254-A | Azole-substituted pyridine compound | 大正制药株式会社 | 2020-03-24 | — | — | CN | disclosed |
| CN-102863512-B | Antiviral compound | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2016-04-20 | — | — | CN | disclosed |
| WO-2013006792-A1 | ANTIVIRAL COMPOUNDS | PHARMARESOURCES (SHANGHAI) CO., LTD. (CN) | 2013-01-10 | — | — | WO | disclosed |
| CN-102863512-A | Novel antiviral compound | SHANGHAI HONGBO ZHIYUAN MEDICAL TECHNOLOGY CO LTD | 2013-01-09 | — | — | CN | disclosed |
| EP-1727789-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | Pfizer Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| WO-2005090287-A2 | PHENYLETHANOLAMINE DERIVATIVES AS BETA-2 AGONISTS | PFIZER LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| EP-1577291-A1 | Phenylethanolamine derivatives as beta-2 agonists | Pfizer Limited (GB) | 2005-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210122741-A1 | PYRIDINE COMPOUND SUBSTITUTED WITH AZOLE | CYP2C19, CYP4A11, CYP11B1 | AKR1B1 85/4885TDP1 4253/4885CYP4F2 20/4885 |
| US-11365192-B2 | Pyridine compound substituted with azole | CYP2C19, CYP4A11, CYP11B1 | AKR1B1 85/4885TDP1 4253/4885CYP4F2 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.